");
A pharmacology and chemistry expert from Priceville helped develop a monoclonal antibody treatment that shows promise in its ability to prevent those with mild cases of COVID-19 from developing complications and requiring hospitalization.
Carl Garner, vice president of global regulatory affairs for pharmaceutical company Eli Lilly and Co., said it typically takes between 18 and 24 months to identify an antibody, conduct research and begin testing it on humans.
âWe did it in about two-and-a-half months,â Garner said. âThe reason why was not that we cut corners, or did anything that would put patients at risk. We put the full force of 145 years of expertise and hundreds of resources toward a single problem in a very focused way.â